Inloggen

Login
 
Wachtwoord vergeten?

Amerikaanse aandelen « Terug naar discussie overzicht

Cannabis aandelen

Volgen
 
Klik hier om dit forumtopic te volgen en automatisch op de hoogte gehouden te worden bij nieuwe berichten.
6.711 Posts, Pagina: « 1 2 3 4 5 6 ... 311 312 313 314 315 316 317 318 319 320 321 ... 332 333 334 335 336 » | Laatste
Aantal posts per pagina:  20 50 100 | Omlaag ↓
zonnedaal
0
quote:

Osho schreef op 15 aug 2019 om 10:15:





capital10x.com/green-organic-dutchman...

TGOD interpretatie van de cijfers en prognose


Hartelijk dank. Ik ken ze. Dit zijn Thomas George en Johnny Lambo. Hebben vorig jaar de short attack op Aphria gecounterd. Interessant om een gratis abbo’tje te nemen op hun mailing list.
Osho
0
quote:

zonnedaal schreef op 15 aug 2019 om 16:34:


[...]

Hartelijk dank. Ik ken ze. Dit zijn Thomas George en Johnny Lambo. Hebben vorig jaar de short attack op Aphria gecounterd. Interessant om een gratis abbo’tje te nemen op hun mailing list.


Ik ga ernaar kijken.

Ben terug ingestapt in ACB (Rond de 6$ gemiddeld NYSE) en heb ook Tgod opgepikt. Nu 'echt' voor de lange termijn. Had voorheen ACB op gemiddeld 9 CAD dus wat verkocht (wat hoog mijn inziens). Dit is een betere prijs.

www.belegger.nl/Column/483946/Buffett... (onze grote vriend koopt bij - Amazon weliswaar - altijd interessant).
Osho
1
quote:

zonnedaal schreef op 15 aug 2019 om 09:33:


CGC moet binnen twee jaar een aandelen buy back van $1,6M uitoefenen (8% van het totaal). Zo niet, dan mag STC 1,6M aan warrants uitoefenen. De afgelopen drie maanden heeft CGC $1,2M hiervan afgeschreven.

Blijf van de fat pigs af (canopy en Tilray). Er zijn veel betere die veel kleiner zijn, de grote investeringen achter de rug hebben en dit kwartaal de eerste winst hebben laten zien (Apha, ACB en volgend jaar TGOD).



Ik zag een flauwe post op twitter vanochtend. Welk aandeel bereikt eerder de 20 CAD -> ACB, Canopy of Aphria (beetje naar voor de Canopy aandeelhouders maar goed). Kon er wel om lachen tijdens deze rode dagen. Hoop doet leven! :D
zonnedaal
0
quote:

Osho schreef op 15 aug 2019 om 17:04:


[...]

Ik zag een flauwe post op twitter vanochtend. Welk aandeel bereikt eerder de 20 CAD -> ACB, Canopy of Aphria (beetje naar voor de Canopy aandeelhouders maar goed). Kon er wel om lachen tijdens deze rode dagen. Hoop doet leven! :D


Heb het gezien :-)

Nadeel van de cannabis sector op Twitter is, dat er enorm veel FUD (Fear, Uncertainty and Doubt) accounts zijn. Pas na een tijdje herken je de meer betrouwbaardere.
DeZwarteRidder
0
De hele sector is gigantisch overgewaardeerd; de koersen moeten nog gedecimeerd worden.
Osho
0
www.marketwatch.com/press-release/aur...

Introduces Aurora Hemp: A Global Hemp Leader Focused on CBD and Organic Hemp Food ProductsEDMONTON, Aug. 19, 2019 /PRNewswire/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (nyse | tsx:ACB), the Canadian company defining the future of cannabis worldwide, is pleased to announce today the completion of the previously announced plan of arrangement (the "Arrangement") with Hempco Food and Fiber Inc. ("Hempco") (HEMP) pursuant to which Aurora has acquired all of the issued and outstanding common shares of Hempco ("Hempco Shares") not already owned by Aurora, reflecting a valuation of approximately C$63.4 million on a fully diluted basis. Hempco is now a wholly-owned subsidiary of Aurora.

- Hempco, a trusted and respected pioneer, innovator and provider of quality, hemp-based foods, hemp fiber, and hemp nutraceuticals. Brands include PLANET HEMP™ and PRAISE, hemp-based foods and nutritional supplements for people and animals. Hempco is nearing completion of a new, state-of-the-art Nisku facility, a 56,000 square foot, 2.9 million kg per year hemp processing facility.

- Agropro, Europe's largest producer of organic hemp and hemp-based food products has extensive experience in sowing seeds, growing, machine harvesting, drying and cleaning biomass in preparation for food processing or extraction into CBD.

- Borela, a processor and distributor across the European Union of organic hulled hemp seeds, hemp seed protein, hemp flour, and hemp seed oil.

- ICC Labs, a Latin American based producer and distributor of cannabinoid products for recreational and medicinal use with operations in Uruguay and Colombia. ICC has access to high CBD hemp genetics available for export to international jurisdictions.
Anandia Labs, the industry leader in science, genetics, and independent cannabis product testing to provide rigorous product testing and quality assurance, ensuring safe and efficacious consumer products.

- Radient Technologies, a provider of industrial-scale manufacturing solutions with a technology platform designed for high extraction and high-volume throughput of cannabinoids available in the plant biomass.

- UFC Clinical Research and Product Development, through this partnership Aurora and UFC will research and examine the use of hemp-derived CBD as an effective treatment for pain, inflammation, wound-healing, and recovery on MMA athletes. Research data will then be used to drive the development of a portfolio of science-backed, high-quality, hemp-derived CBD topical treatments, under the new high-performance sports brand ROAR Sports.

Dit is een mooie lijst.
zonnedaal
0
Hedge Fund Legend Jim Simons Pours Money Into Aurora Cannabis (ACB) and Aphria (APHA) Stocks

n the last two quarters, billionaire, hedge fund manager, and mathematical genius Jim Simons has moved decisively into the cannabis sector, taking large positions in both Aurora Cannabis (ACB) and Aphria (APHA).

Simons, known for his work in higher mathematics and military cryptography, founded the Renaissance Technologies hedge fund in 1982. The firm was a pioneer in quantitative trading, the application of higher mathematics to the financial markets, and has developed a reputation as one of the best returning hedge funds in the business. Simons retired from active direction of the company in 2009, but continues as non-executive chairman in an advisory role.

Simons’ new positions in cannabis are considerable. Per the 13F filings, his firm purchased 788,595 shares of ACB, for $6.3 million, in Q1, and followed up in Q2 with an additional 905,305 shares at $7.1 million. Also in Q2, Simons picked up 241,500 shares of Aphria, at $1.7 million. Clearly, Simons sees something of value in the cannabis sector.

Even the Skeptics See Potential in Aurora Cannabis

Writing earlier this month, 4-star analyst Rommel Dionisio of Compass Point noted Aurora’s (ACB) high quarterly production and strong brand presence in the Canadian marijuana market. Aurora reported nearly 30,000 kilos of cannabis production in the last quarter, significantly more than the previous guidance of 25,000, and making Aurora one of the world’s largest medical/recreational cannabis producers.

Dionisio hedges his bets on Aurora. He rates ACB as a Hold, but gives the stock a $8 price target, indicating a 33.5% upside from the current share price of $5.99. The analyst sees plenty of growth potential in Aurora’s strong production and hefty market share – all factors that brought Renaissance Technologies into this stock, as well.

On the negative side of the ledger, Aurora lowered guidance of fiscal Q4 revenue, from $111 million to the range of $100 to $107 million. The reduction in revenue guidance comes even as the company is ramping up production, and Dionisio attributes it to “modest pricing pressure” as supplies increase in the Canadian market.

Summing up Aurora’s situation, Dionisio says, “Aurora enjoys the second leading share of the important Canadian market, with approximately 20% market share in both the recreational and medical use markets. Moreover, through a series of acquisitions and license wins, Aurora has become one of the global front-runners in establishing an early presence in several countries in Europe and Latin America. Aurora … appears well positioned to remain one of the leading companies in the global cannabis industry, and as such warrants a premium valuation…”

Overall, ACB gets a Moderate Buy rating from the analyst consensus, based on 3 buys and 4 holds given in the past three months. As mentioned, shares are selling for $5.99, so the $8.68 average price target suggests an upside of 45%. It’s important to note here that even the low-end price target, of $7, still suggests an upside of 16%, so even the true skeptics see some potential in the stock.

finance.yahoo.com/news/jim-simons-pou...
DeZwarteRidder
0
quote:

zonnedaal schreef op 19 aug 2019 om 14:18:


Hedge Fund Legend Jim Simons Pours Money Into Aurora Cannabis (ACB) and Aphria (APHA) Stocks

n the last two quarters, billionaire, hedge fund manager, and mathematical genius Jim Simons has moved decisively into the cannabis sector, taking large positions in both Aurora Cannabis (ACB) and Aphria (APHA).

Simons, known for his work in higher mathematics and military cryptography, founded the Renaissance Technologies hedge fund in 1982. The firm was a pioneer in quantitative trading, the application of higher mathematics to the financial markets, and has developed a reputation as one of the best returning hedge funds in the business. Simons retired from active direction of the company in 2009, but continues as non-executive chairman in an advisory role.

Simons’ new positions in cannabis are considerable. Per the 13F filings, his firm purchased 788,595 shares of ACB, for $6.3 million, in Q1, and followed up in Q2 with an additional 905,305 shares at $7.1 million. Also in Q2, Simons picked up 241,500 shares of Aphria, at $1.7 million. Clearly, Simons sees something of value in the cannabis sector.

Even the Skeptics See Potential in Aurora Cannabis

Writing earlier this month, 4-star analyst Rommel Dionisio of Compass Point noted Aurora’s (ACB) high quarterly production and strong brand presence in the Canadian marijuana market. Aurora reported nearly 30,000 kilos of cannabis production in the last quarter, significantly more than the previous guidance of 25,000, and making Aurora one of the world’s largest medical/recreational cannabis producers.

Dionisio hedges his bets on Aurora. He rates ACB as a Hold, but gives the stock a $8 price target, indicating a 33.5% upside from the current share price of $5.99. The analyst sees plenty of growth potential in Aurora’s strong production and hefty market share – all factors that brought Renaissance Technologies into this stock, as well.

On the negative side of the ledger, Aurora lowered guidance of fiscal Q4 revenue, from $111 million to the range of $100 to $107 million. The reduction in revenue guidance comes even as the company is ramping up production, and Dionisio attributes it to “modest pricing pressure” as supplies increase in the Canadian market.

Summing up Aurora’s situation, Dionisio says, “Aurora enjoys the second leading share of the important Canadian market, with approximately 20% market share in both the recreational and medical use markets. Moreover, through a series of acquisitions and license wins, Aurora has become one of the global front-runners in establishing an early presence in several countries in Europe and Latin America. Aurora … appears well positioned to remain one of the leading companies in the global cannabis industry, and as such warrants a premium valuation…”

Overall, ACB gets a Moderate Buy rating from the analyst consensus, based on 3 buys and 4 holds given in the past three months. As mentioned, shares are selling for $5.99, so the $8.68 average price target suggests an upside of 45%. It’s important to note here that even the low-end price target, of $7, still suggests an upside of 16%, so even the true skeptics see some potential in the stock.

finance.yahoo.com/news/jim-simons-pou...

Ik denk dat Jim teveel wiet heeft gerookt.........
Chappie69
0
quote:

DeZwarteRidder schreef op 19 aug 2019 om 14:22:


[...]
Ik denk dat Jim teveel wiet heeft gerookt.........


Zou je beter ook doen ridder....dan lijken je AMG's ook plots een stuk vrolijker....
Businessmen
0
Vandaag Canopy weer erbij gekocht. Dit aandeel is spot goedkoop geworden. Onthoud na dalen komt altijd stijging
DeZwarteRidder
0
quote:

Businessmen schreef op 19 aug 2019 om 21:57:


Vandaag Canopy weer erbij gekocht. Dit aandeel is spot goedkoop geworden. Onthoud na dalen komt altijd stijging

Canopy is PEPERDUUR....!!!

Beurswaarde is ca 12,5 MILJARD bij een omzet van ca 400 miljoen.

Bovendien verbranden ze ca een half miljard per jaar (geen weed, maar geld!)
Rider
0
quote:

DeZwarteRidder schreef op 19 aug 2019 om 22:53:


[...]
Canopy is PEPERDUUR....!!!

Beurswaarde is ca 12,5 MILJARD bij een omzet van ca 400 miljoen.

Bovendien verbranden ze ca een half miljard per jaar (geen weed, maar geld!)



9miljard, maar idd wel duur. Geef mij maar Aurora staat ook niet goedkoop maar hun omzet stijgt enorm snel en Alefia is één die wel goedkoop is.
DeZwarteRidder
0
quote:

Rider schreef op 20 aug 2019 om 06:16:


[...]9miljard, maar idd wel duur. Geef mij maar Aurora staat ook niet goedkoop maar hun omzet stijgt enorm snel en Alefia is één die wel goedkoop is.

Uitst. Aandelen 346.658.913 X 35,5 = 12,4 miljard CAD.
Rider
0
quote:

DeZwarteRidder schreef op 20 aug 2019 om 08:27:


[...]
Uitst. Aandelen 346.658.913 X 35,5 = 12,4 miljard CAD.


Er is nog 3 miljard cash.
wuiten001
0
Harvest One Launches New Satipharm CBD Oil
Available Across Europe for Online Sales

August 19, 2019 – Vancouver, British Columbia – Harvest One Cannabis Inc. ("Harvest One" or the "Company") (TSXV: HVT; OTCQX: HRVOF), through its wholly-owned subsidiary Satipharm Ltd. (“Satipharm”) today announced it has expanded its product portfolio with the launch of CBD oil, now available online at www.satipharm.com. Brick and mortar distribution will follow with major retailers throughout Europe.

The new European oils program has begun with a Lemon & Lime flavoured CBD oil. Satipharm expects to expand this program with more varieties in the coming months. Satipharm CBD oils join the existing CBD Gelpell® capsules, already available across Europe online and in 1,800 stores across the UK and Ireland. All of Satipharm’s products in Europe are EU GMP certified to ensure the highest standards.

The Satipharm Lemon & Lime CBD oil was specifically formulated to address three major concerns from consumers, which are taste, GMP certification, and reliable dosage.

“Product innovation is essential to building our brands. Our new CBD oil illustrates continued movement by Harvest One towards our strategy of building health, wellness, and self-care brands around the world,” said Grant Froese, Chief Executive Officer of Harvest One. “Customers can have the same confidence in new Satipharm CBD oils as they do in our existing Satipharm CBD Gelpell® already on the market across Europe."


Further to Harvest One’s press release dated June 21, 2019 (See SEDAR for full disclosure) in respect to a shares-for-services agreement, the Company has issued 131,710 common shares at a price of $0.57 per share.

About Harvest One Cannabis
Harvest One is a global consumer packaged goods company that develops and distributes premium health, wellness, and lifestyle products to patients and consumers in regulated markets around the world. The Company's portfolio of premium products is designed to enhance quality of life. Shareholders have significant exposure to the entire cannabis value chain through four wholly-owned subsidiaries: United Greeneries, a Licensed Producer; Satipharm (medical and nutraceutical); Dream Water Global and Delivra (consumer products with an emphasis on sleep, pain, and anxiety), and a minority interest in Burb Cannabis (retail operations). For more information, please visit www.harvestone.com.

About Satipharm
Satipharm is a health and wellness company which is specialised in the development and manufacture of cannabinoid-based products from the cannabis plant. Our mission is to deliver the highest quality products that are designed specifically with the needs of our customers in mind. For more information, please visit www.satipharm.com.



ikketje88
0
Wat zijn jullie algemene verwachtingen over de cannabisaandelen? Ze blijven maar dalen...
DeZwarteRidder
0
quote:

ikketje88 schreef op 23 aug 2019 om 15:39:


Wat zijn jullie algemene verwachtingen over de cannabisaandelen? Ze blijven maar dalen...

Volledig volgens verwachting.
6.711 Posts, Pagina: « 1 2 3 4 5 6 ... 311 312 313 314 315 316 317 318 319 320 321 ... 332 333 334 335 336 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Markt vandaag

Wall Street in mineur

18 okt De Amerikaanse aandelenbeurzen stonden vrijdag tijdens de middaghandel in New York op verlies. Beleggers op...

    Indices

    AEX 572,72 -0,62%
    EUR/USD 1,1171 +0,40%
    Germany30^ 12.652,90 -0,02%
    Gold spot 1.490,06 0,00%
    LDN100-24h 7.143,88 0,00%
    NY-Nasdaq Composite 8.089,54 -0,83%
    US30# 26.807,69 +0,12%

    Stijgers

    Sligro
    +4,94%
    Flow T...
    +2,87%
    Pharming
    +2,66%
    Accell
    +2,30%
    SIGNIF...
    +2,12%

    Dalers

    Kiadis...
    -50,79%
    ForFar...
    -5,05%
    Galapagos
    -4,06%
    RELX
    -3,00%
    TomTom
    -2,97%